Table 7:
DPYD Carriers With a Genotype-Guided Reduced Fluoropyrimidine Dose Versus Wild-Type Patients—Treatment Modifications
| Author, Year N (Carrier/Wild-Type) | Initial Dose Reduction | Additional Dose Reductions, n (%) | Dose Increase, n (%) |
|---|---|---|---|
| Wigle et al, 202171 1,394 (47/1,347) |
Mean % of standard dose (SD) Carriers: 52 (18.0) Wild-type: 87.4 (15.2) |
NR | NR |
| Henricks et al, 201911 1,646 (40/1,606) |
Mean % of standard dose Carrier: 53 Wild-type: 92 |
Carrier: 7 (17.5) Wild-type: NR |
Carrier: 11 (27.5) Wild-type: NR |
| Kleinjan et al, 201912 185 (11/174) |
NR | Carrier: 2 (18.2); 1 because of severe toxicity after dose increase Wild-type: NR |
Carrier: 6 (54.5) Wild-type: |
| Stavraka et al, 201923 63 (2/61) |
Dose reductions, n (%) Carrier: 2 (100) Wild-type, n (%): 9 (14.8) |
Carrier: 0 Wild-type: NR |
Carrier: 2 (100); 1 (50) had grade 3 toxicity with increased dose and treatment was stopped Wild-type: 0 |
| Henricks et al, 201872 1,103 (85/1,018) |
Mean % of standard dose (range) Carrier: 69 (37–97) Wild-type: 94 (49–128) |
Carrier: 5 (5.9%); because of toxicity after dose increase | Carrier: 11 (12.9) Wild-type: 31 (3.0) |
| Lunenburg et al, 20187 827 (22a/771/34b) |
NR | Carrier: 2 (9.1) Wild-type: 34 (4.4) Carriera: 4 (11.8) |
Carrier: 2 (9.1) Wild-type: 4 (0.5) Carriera: NR |
Abbreviation: NR, not reported; SD, standard deviation.
a
One patient was excluded from the analyses.
b
DPYD carriers who received a standard dose.